Rada Electronic Industries (RADA) is trading at unusually high volume Wednesday with 7.18 million shares changing hands. It is currently at more than 3x its average daily volume and trading up 8% at $3.40. The name is up on Israeli Iron Dome deployment news.
Rada Electronic is an Israel-based defense electronics contractor engaged in the development of defense electronics to various air forces and companies worldwide. Its stock has a 52-week trading range of $1.26 to $6.29. The T-12 operating margin at Rada Electronic is 6.68%. The name‘s revenue for the same period is $22.95 million. Rada Electronic’s price/book is 7.22.
Shares in the $30.23 million company are up 102% year-over-year, and 131% year-to-date.
Micronet Enertec Technologies, Inc. (MICT) moving higher intraday on a report stating that Iron Dome has been deployed in Israel. Micronet systems and technology are embedded in the Arrow and Iron Dome missile programs as well as in naval platforms.
MICT shares recently gained $0.20, or 5.36%, to $3.96. The thinly traded stock is down more than 12.56% year-over-year, and has lost roughly 26.27% year-to-date. In the past 52 weeks, shares of Montvale, New Jersey-based company have traded between a low of $2.58 and a high of $6.37.
Micronet Enertec Technologies, which closed Tuesday at $3.76, has a total market cap of $23.09M.
Biocept, Inc. (BIOC) is a big mover this session with its shares spiking nearly 43% on the day. The move comes on solid volume too with the issue currently trading more than 139K shares, which dwarfs the average volume of 20,722. Biocept today announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory.
On trading-measure, BIOC has a beta of 0.87 and a short float of 0.24%. In the past 52 weeks, shares of San Diego, California-based company have traded between a low of $2.27 and a high of $10.02 with the 50-day MA and 200-day MA located at $2.91 and $4.43 levels, respectively.
Biocept, Inc. gained $1.31 to $4.05 in mid-day trading today. The name is down 58.51% year-to-date.
Twitter Inc (TWTR) shares edged higher in mid-day trading after the social media company outlined its plan to attract new users at its ‘Analyst Day’.
CEO Dick Costolo said the company would unveil new products to attract new users and others who don’t typically pay attention to the micro-blogging service, as it tries to extend its reach outside of its normal user base, according to Bloomberg.
Twitter gained $3.27 to $42.86 in mid-day trading today. Approximately 33.10M shares have already changed hands, compared to the stock’s average daily volume of 26.17M shares.
TWTR currently prints a one year loss of about 7.72%, and a year-to-date loss of around 37.80%.
Investment analysts at Canaccord Genuity initiated coverage on shares of Agios Pharmaceuticals, Inc. (AGIO) in a note issued to investors on Wednesday. The firm set a ‘Buy’ rating and a $97 price target on the stock. The firm’s price target would suggest a potential upside of 11% from the stock’s current price.
Agios Pharmaceuticals gained $5.35 to $87.26 in mid-day trading today. Approximately 1.23M shares have already changed hands, compared to the stock’s average daily volume of 650.88K shares.
On valuation-measures, shares of Agios Pharmaceuticals, Inc. have a T-12 profit margin of (68.25%) and price/sales valuation measure of 49.44. EPS registers at ($1.83). The company has a market cap of $3.03B and a median Wall Street price target of $83.00 with a high target of $93.00.
On trading-measure, AGIO has a beta of 1.98 and a short float of 17.09%. In the past 52 weeks, shares of Cambridge, Massachusetts-based biopharmaceutical company have traded between a low of $15.77 and a high of $89.50 with the 50-day MA and 200-day MA located at $69.71 and $48.46 levels, respectively.
AGIO currently prints a one year return of about 292.10%, and a year-to-date return of around 242.00%.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply